Question
The first approved treatment for primary progressive multiple sclerosis, ocrelizumab, targets this antigen. For 10 points each:
[10m] Name this antigen found on the surface of B cells. This antigen is targeted by the first antibody approved for cancer patients, rituximab.
ANSWER: CD20 [accept MS4A1]
[10h] In addition to attracting NK cells in antibody-dependent cellular cytotoxicity, rituximab also induces complement-dependent cytotoxicity, likely by recruiting this protein complex that binds to antibody-antigen complexes to initiate the classical complement pathway.
ANSWER: C1 [or complement component 1; accept C1q or complement component 1q]
[10e] The suffix “-mab” in rituximab and ocrelizumab refers to them being medicines composed of these antibodies. Fused hybridomas produce these antibodies which target a single epitope.
ANSWER: monoclonal antibodies [or mAb]
<Science - Biology>
Summary
| 2024 ARGOS @ Brandeis | 03/22/2025 | Y | 3 | 6.67 | 67% | 0% | 0% |
| 2024 ARGOS @ Christ's College | 12/14/2024 | Y | 3 | 10.00 | 100% | 0% | 0% |
| 2024 ARGOS @ Stanford | 02/22/2025 | Y | 3 | 10.00 | 100% | 0% | 0% |
| 2024 ARGOS Online | 03/22/2025 | Y | 3 | 10.00 | 100% | 0% | 0% |
Data
| Aw we're so sorry to hear that maman died today, she gets five big booms | CLEVELAND, THIS IS FOR YOU! | 0 | 0 | 10 | 10 |
| I wish it were possible to freeze time so I would never have to watch you retire | Thompson et al. | 0 | 0 | 10 | 10 |
| throw away your cards, rally in the streets | UBC | 0 | 0 | 10 | 10 |